[Multiple sclerosis. What about treatment with monoclonal antibodies?].
Marignier
Romain
R
Service de neurologie A, centre de coordination EDMUS pour la sclérose en plaques, hôpital neurologique Pierre-Wertheimer, CHU de Lyon, 69677 Bron Cedex. romain.marignier@chu-lyon.fr
Confavreux
Christian
C
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D007155:Immunologic Factors; D000069442:Natalizumab; D000074323:Alemtuzumab; D000069283:Rituximab; D000077561:Daclizumab